IL2_SHEEP
ID IL2_SHEEP Reviewed; 155 AA.
AC P19114; A0MZP0; Q95MP4;
DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT 27-MAY-2002, sequence version 2.
DT 03-AUG-2022, entry version 116.
DE RecName: Full=Interleukin-2;
DE Short=IL-2;
DE AltName: Full=T-cell growth factor;
DE Short=TCGF;
DE Flags: Precursor;
GN Name=IL2;
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=2216781; DOI=10.1093/nar/18.19.5883;
RA Goodall J.C., Emery D.C., Perry A.C.F., English L.S., Hall L.;
RT "cDNA cloning of ovine interleukin 2 by PCR.";
RL Nucleic Acids Res. 18:5883-5883(1990).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=2263496; DOI=10.1093/nar/18.23.7175;
RA Seow H.F., Rothel J.S., Radford A.J., Wood P.R.;
RT "The molecular cloning of ovine interleukin 2 gene by the polymerase chain
RT reaction.";
RL Nucleic Acids Res. 18:7175-7175(1990).
RN [3]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=11048943; DOI=10.2527/2000.78102754x;
RA Luehken G., Hiendleder S., Prinzenberg E.M., Erhardt G.;
RT "A single-strand conformation polymorphism in the ovine interleukin-2 (IL-
RT 2) gene.";
RL J. Anim. Sci. 78:2754-2755(2000).
RN [4]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA Luehken G., Erhardt G.;
RT "Molecular characterization of Ovis aries IL2.";
RL Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 21-153.
RX PubMed=7543777; DOI=10.1006/cyto.1995.0025;
RA Bujdoso R., Williamson M.L., Roy D., Hunt P., Blacklaws B., Sargan D.,
RA McConnell I.;
RT "Molecular cloning and expression of DNA encoding ovine interleukin 2.";
RL Cytokine 7:223-231(1995).
CC -!- FUNCTION: Cytokine produced by activated CD4-positive helper T-cells
CC and to a lesser extend activated CD8-positive T-cells and natural
CC killer (NK) cells that plays pivotal roles in the immune response and
CC tolerance. Binds to a receptor complex composed of either the high-
CC affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RG/CD132) or
CC the low-affinity dimeric IL-2R (IL2RB and IL2RG). Interaction with the
CC receptor leads to oligomerization and conformation changes in the IL-2R
CC subunits resulting in downstream signaling starting with
CC phosphorylation of JAK1 and JAK3. In turn, JAK1 and JAK3 phosphorylate
CC the receptor to form a docking site leading to the phosphorylation of
CC several substrates including STAT5. This process leads to activation of
CC several pathways including STAT, phosphoinositide-3-kinase/PI3K and
CC mitogen-activated protein kinase/MAPK pathways. Functions as a T-cell
CC growth factor and can increase NK-cell cytolytic activity as well.
CC Promotes strong proliferation of activated B-cells and subsequently
CC immunoglobulin production. Plays a pivotal role in regulating the
CC adaptive immune system by controlling the survival and proliferation of
CC regulatory T-cells, which are required for the maintenance of immune
CC tolerance. Moreover, participates in the differentiation and
CC homeostasis of effector T-cell subsets, including Th1, Th2, Th17 as
CC well as memory CD8-positive T-cells. {ECO:0000250|UniProtKB:P60568}.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the IL-2 family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; X53934; CAA37881.1; -; mRNA.
DR EMBL; X55641; CAA39165.1; -; mRNA.
DR EMBL; AF287479; AAK69554.1; -; Genomic_DNA.
DR EMBL; EF056466; ABK41601.1; -; Genomic_DNA.
DR EMBL; X60148; CAA42722.1; -; mRNA.
DR PIR; S11488; S11488.
DR RefSeq; NP_001009806.1; NM_001009806.1.
DR AlphaFoldDB; P19114; -.
DR SASBDB; P19114; -.
DR SMR; P19114; -.
DR Ensembl; ENSOART00020016981; ENSOARP00020014020; ENSOARG00020011086.
DR GeneID; 443401; -.
DR KEGG; oas:443401; -.
DR CTD; 3558; -.
DR OrthoDB; 947117at2759; -.
DR Proteomes; UP000002356; Unplaced.
DR GO; GO:0005615; C:extracellular space; IEA:UniProtKB-KW.
DR GO; GO:0005125; F:cytokine activity; IEA:UniProtKB-KW.
DR GO; GO:0008083; F:growth factor activity; IEA:UniProtKB-KW.
DR GO; GO:0005134; F:interleukin-2 receptor binding; IEA:Ensembl.
DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR GO; GO:0002366; P:leukocyte activation involved in immune response; IEA:Ensembl.
DR GO; GO:0002903; P:negative regulation of B cell apoptotic process; IEA:Ensembl.
DR GO; GO:0042104; P:positive regulation of activated T cell proliferation; IEA:Ensembl.
DR GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR GO; GO:0002639; P:positive regulation of immunoglobulin production; IEA:Ensembl.
DR GO; GO:0032740; P:positive regulation of interleukin-17 production; IEA:Ensembl.
DR GO; GO:1900100; P:positive regulation of plasma cell differentiation; IEA:Ensembl.
DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IEA:Ensembl.
DR Gene3D; 1.20.1250.10; -; 1.
DR InterPro; IPR009079; 4_helix_cytokine-like_core.
DR InterPro; IPR000779; IL-2.
DR InterPro; IPR030477; IL-2_CS.
DR Pfam; PF00715; IL2; 1.
DR PRINTS; PR00265; INTERLEUKIN2.
DR SMART; SM00189; IL2; 1.
DR SUPFAM; SSF47266; SSF47266; 1.
DR PROSITE; PS00424; INTERLEUKIN_2; 1.
PE 2: Evidence at transcript level;
KW Adaptive immunity; Cytokine; Disulfide bond; Glycoprotein; Growth factor;
KW Immunity; Reference proteome; Secreted; Signal.
FT SIGNAL 1..20
FT /evidence="ECO:0000250"
FT CHAIN 21..155
FT /note="Interleukin-2"
FT /id="PRO_0000015502"
FT CARBOHYD 23
FT /note="O-linked (GalNAc...) threonine"
FT /evidence="ECO:0000250"
FT DISULFID 79..127
FT /evidence="ECO:0000250"
FT CONFLICT 6
FT /note="L -> P (in Ref. 1; CAA37881)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 155 AA; 17678 MW; 3F76C6CBB7B289C5 CRC64;
MYKIQLLSCI ALTLALVANG APTSSSTGNT MKEVKSLLLD LQLLLEKVKN PENLKLSRMH
TFNFYMPKVN ATELKHLKCL LEELKLLEEV LDLAPSKNLN TREIKDSMDN IKRIVLELQG
SETRFTCEYD DATVKAVEFL NKWITFCQSI YSTMT
